You are here

Hatteras Venture Partners

Founding Member

Robert A. Ingram

General Partner, Hatteras Venture Partners; Founding Chairman, CEO Roundtable on Cancer

Bob Ingram joined the firm of Hatteras Venture Partners as a General Partner on January 24, 2007.  Hatteras Venture Partners is a venture capital firm that invests in early stage life science companies in the southeast United States.

Bob began his career in the pharmaceutical industry as a professional sales representative and rose through a series of roles with increasing responsibility to ultimately become CEO/Chairman of GlaxoWellcome.  He co-led the merger and integration that formed GlaxoSmithKline, the world’s second largest pharmaceutical company.  Upon reaching the mandatory retirement age of 60, he was asked by the Board to serve as Vice Chairman Pharmaceuticals, GSK, which he did until January 1, 2010, at which time he became Strategic Advisor to the Chief Executive Officer, GlaxoSmithKline plc.  

He serves as Lead Director of Valeant Pharmaceuticals International and Cree, Inc.  He is also a member of the Board of Directors of Edwards Lifesciences Corporation and Regeneron Pharmaceuticals, Inc. and is Chairman of Viamet, a private company focused on anti-infective research. 

In addition to his professional responsibilities, Bob was asked by former US President George H.W. Bush to form and chair the CEO Roundtable on Cancer. He is a member of numerous other civic and professional organizations. In January 2004, Bob was awarded the Martin Luther King, Jr. Legacy Award for International Service.  On July 27, 2006, he was appointed by President George W. Bush to the National Institutes of Health, National Cancer Advisory Board.  

Bob is a member of the Boards for the James B. Hunt Jr. Institute for Educational Leadership and Policy, H. Lee Moffitt Cancer Center, CEO Roundtable on Cancer, Research Triangle Institute and Chairman, GlaxoSmithKline Foundation.  He serves as Chairman of Research Triangle Foundation of North Carolina and is on the Advisory Board, Leonard D. Schaeffer Center for Health Policy & Economics, University of Southern California.

Bob graduated from Eastern Illinois University with a BS degree in Business Administration.

CEO Roundtable on Cancer

Board of Directors

Robert A. Ingram, Founding Chairman, is a Member of the CEO Roundtable on Cancer Board of Directors

Kenneth A. Lee, serves as Chief Financial Officer (pro bono) of the CEO Roundtable on Cancer

CEO Cancer Gold Standard™

Gold Standard  Employer

Since 2016


The CEO Cancer Gold Standard is the best way I know for any organization to make a real difference in the fight against cancer.

— Robert A. Ingram

Gold Standard  Task Force Participation

Task Force Member(s): Alison Fulghum, Executive Assistant to Mr. Thorp

Life Sciences Consortium

LSC  Task Force Participation

Task Force Member(s): Robert A. Ingram

Project Data Sphere, LLC

an independent initiative of the Life Sciences Consortium

Executive Leadership Team

Robert A. Ingram, 2nd Vice President

Hatteras Venture Partners

Hatteras Venture Partners is a venture capital firm formed to invest primarily in early stage companies with a focus on biopharmaceuticals, medical devices, diagnostics, healthcare IT, and related opportunities in human medicine. The firm will typically invest in companies located in the research-driven regions of North Carolina and the Southeastern United States, which are undercapitalized in comparison to New England and California.

Core to the mission of Hatteras Venture Partners is a belief that entrepreneurial innovation will create valuable new products that will transform the practice of medicine and create value for our investors. As entrepreneurs, operators, and investors, we are dedicated to the success of our companies and to the men and women who create them.

Founded in 2000 and based in Durham, NC, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to building successful new biomedical companies. The Hatteras team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With five funds, the firm has approximately $350 million under management.

Hatteras is an Innovation to Impact sponsor of the Council for Entrepreneurial Development, a member of NCBIO, and an active volunteer in support of North Carolina and Southeast regional biotech activities.